Advertisement

Topics

PAREXEL International Enters Definitive Agreement to Be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash

07:05 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Pamplona Capital Management, LLP (Pamplona) today announced that they have entered into a definitive agreement under whi...

Other Sources for this Article

For PAREXEL
Media:
Mark Stephenson
Tel.: +1 781-434-4783
Email: Mark.Stephenson@PAREXEL.com
or
Barrett Golden / Arielle Rothstein
Joele Frank, Wilkinson Brimmer Katcher
Tel.: +1 212-355-4449
or
Investors:
Ronald Aldridge
Tel.: +1-781-434-4753
Email: ron.aldridge@PAREXEL.com
or
For Pamplona
Ed Orlebar
Temple Bar Advisory (PR advisor to Pamplona)
Tel.: +44-773-872-4630
Email: edo@templebaradvisory.com

NEXT ARTICLE

More From BioPortfolio on "PAREXEL International Enters Definitive Agreement to Be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...